241 related articles for article (PubMed ID: 22440918)
1. Anti-HCV drugs in the pipeline.
Yang PL; Gao M; Lin K; Liu Q; Villareal VA
Curr Opin Virol; 2011 Dec; 1(6):607-16. PubMed ID: 22440918
[TBL] [Abstract][Full Text] [Related]
2. Profile of alisporivir and its potential in the treatment of hepatitis C.
Gallay PA; Lin K
Drug Des Devel Ther; 2013; 7():105-15. PubMed ID: 23440335
[TBL] [Abstract][Full Text] [Related]
3. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
Chatterji U; Garcia-Rivera JA; Baugh J; Gawlik K; Wong KA; Zhong W; Brass CA; Naoumov NV; Gallay PA
Antimicrob Agents Chemother; 2014 Jun; 58(6):3327-34. PubMed ID: 24687498
[TBL] [Abstract][Full Text] [Related]
4. Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance.
Mathy JE; Ma S; Compton T; Lin K
Antimicrob Agents Chemother; 2008 Sep; 52(9):3267-75. PubMed ID: 18591281
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
[TBL] [Abstract][Full Text] [Related]
6. SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection.
Li X; Han J; Lee HW; Yoon YS; Jin Y; Khadka DB; Yang S; Kim M; Cho WJ
Bioorg Med Chem; 2020 Oct; 28(19):115679. PubMed ID: 32912430
[TBL] [Abstract][Full Text] [Related]
7. Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.
Berger KL; Sarrazin C; Nelson DR; Scherer J; Sha N; Marquis M; Côté-Martin A; Vinisko R; Stern JO; Mensa FJ; Kukolj G
PLoS One; 2016; 11(8):e0160668. PubMed ID: 27494410
[TBL] [Abstract][Full Text] [Related]
8. HCV1b genome evolution under selective pressure of the cyclophilin inhibitor alisporivir during the DEB-025-HCV-203 phase II clinical trial.
Cuypers L; Snoeck J; Kerremans L; Libin P; Crabbé R; Van Dooren S; Vuagniaux G; Vandamme AM
Infect Genet Evol; 2016 Oct; 44():169-181. PubMed ID: 27374748
[TBL] [Abstract][Full Text] [Related]
9. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
[TBL] [Abstract][Full Text] [Related]
10. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A.
Coelmont L; Hanoulle X; Chatterji U; Berger C; Snoeck J; Bobardt M; Lim P; Vliegen I; Paeshuyse J; Vuagniaux G; Vandamme AM; Bartenschlager R; Gallay P; Lippens G; Neyts J
PLoS One; 2010 Oct; 5(10):e13687. PubMed ID: 21060866
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
12. Directly acting antivirals against hepatitis C virus.
Soriano V; Vispo E; Poveda E; Labarga P; Martin-Carbonero L; Fernandez-Montero JV; Barreiro P
J Antimicrob Chemother; 2011 Aug; 66(8):1673-86. PubMed ID: 21652618
[TBL] [Abstract][Full Text] [Related]
13. Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care?
Zeuzem S; Nelson DR; Marcellin P
Antivir Ther; 2008; 13(6):747-60. PubMed ID: 18839776
[TBL] [Abstract][Full Text] [Related]
14. Targets for antiviral therapy of hepatitis C.
Rupp D; Bartenschlager R
Semin Liver Dis; 2014 Feb; 34(1):9-21. PubMed ID: 24782254
[TBL] [Abstract][Full Text] [Related]
15. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
Halfon P; Sarrazin C
Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
[TBL] [Abstract][Full Text] [Related]
16. Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection.
Sundaram V; Kowdley KV
Expert Rev Gastroenterol Hepatol; 2016; 10(1):13-20. PubMed ID: 26560449
[TBL] [Abstract][Full Text] [Related]
17. [Attempts to treat chronic hepatitis C with HCV protease inhibitor].
Pawłowska M
Przegl Epidemiol; 2011; 65(1):35-8. PubMed ID: 21735833
[TBL] [Abstract][Full Text] [Related]
18. New NS5B polymerase inhibitors for hepatitis C.
Legrand-Abravanel F; Nicot F; Izopet J
Expert Opin Investig Drugs; 2010 Aug; 19(8):963-75. PubMed ID: 20629614
[TBL] [Abstract][Full Text] [Related]
19. Treatment of chronic hepatitis C: current and future.
Pawlotsky JM
Curr Top Microbiol Immunol; 2013; 369():321-42. PubMed ID: 23463207
[TBL] [Abstract][Full Text] [Related]
20. Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase.
Pawlotsky JM; Najera I; Jacobson I
Antivir Ther; 2012; 17(3):411-23. PubMed ID: 22402762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
